Pathologic consequences of increased angiotensin II activity

Cardiovascular Drugs and Therapy

Volumn 10, Issue 5, 1996, Pages 511-518

  Ferrario, Carlos M ^a   Flack, John M ^a  

^a North Carolina Baptist Hospital   (United States)

Author keywords

Angiotensin II; Angiotensin receptor blocker; AT1 receptor; AT2 receptor; Hypertension; Losartan; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; LOSARTAN; NITRIC OXIDE; PROSTAGLANDIN;

ARTICLE; CARDIOVASCULAR FUNCTION; CELL ONCOGENE; ELECTROLYTE BALANCE; ESSENTIAL HYPERTENSION; HEADACHE; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOCONSTRICTION; VERTIGO;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0029857276     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00050990     Document Type: Article

References (100)

1. Ondetti MA, Cushman DW. Enzymes of the renin angiotensin system and their inhibitors. Annu Rev Biochem 1982;51:238-252.
2. Page IH. The mosaic theory of arterial hypertension - its interpretation. Perspect Biol Med 1967;10:3-33.
3. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-69.
4. Charru A, Jeunemaitre X, Soubrier F, Corvol P, Chatellier G. Hypergene: A clinical and genetic database for genetic analysis of human hypertension. J Hypertens 1994; 12:981-985.
5. Harrap SB, Davidson HR, Connor JM, et al. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993;21:455-460.
6. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992;71:169-180.
7. Ferrario CM. The renin-angiotensin system: Importance in physiology and pathology. In: Saruta T, Arakawa K, Kokubu T, eds. ACE inhibitors: Innovative clinical applications. Japan: Medical Tribune, 1990:66-79.
8. Ferrario CM, Barnes KL, Block CH, et al. Pathways of angiotensin formation and function in the brain. Hypertension 1990;15(Suppl I):I13-I19.
9. Ferrario CM, Chapped MC. A new myocardial conversion of angiotensin I. Curr Opin Cardiol 1994;9:520-526.
10. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens 1994;12(Suppl): S17-S22.
11. Ferrario CM. Biological roles of angiotensin-(1-7). Hypertens Res 1992;15:61-66.
12. Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995;25:796-802.
13. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) [Ang-(1-7)] inhibits vascular smooth muscle cell growth (abstract). Hypertension 1995;22:414.
14. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides 1993;14:679-684.
15. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-T) in spontaneously hypertensive rats. Am J Physiol 1995;269(1 Pt 2): H313-H319.
16. Moriguchi A, Tallant EA, Matsumura K, et al. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 1995;25: 1260-1265.
17. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic actions of angiotensin-(1-7). Br J Pharmacol 1994;111:1-3.
18. Andreatta-Van Leyen S, Romero MF, Khosla MC, Douglas JG. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). Kidney Int 1993;44: 932-936.
19. Botelho LMO, Block CH, Khosla MC, Santos RAS. Plasma angiotensin (1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides 1994;15:723-729.
20. Heyne N, Beer W, Muhlbauer B, Osswald H. Renal response to angiotensin-(1-7) in anesthetized rats (abstract). Kidney Int 1995;47:975-976.
21. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993;52:1461-1480.
22. Ferrario CM. Renin-angiotensin system: Importance in physiology and pathology. J Cardiovasc Pharmacol 1990; 15(Suppl 3):S1-S5.
23. Ferrario CM, Jaiswal N, Yamamoto K, Diz DI, Schiavone MT. Hypertensive mechanisms and converting enzyme inhibitors. Clin Cardiol 1991;14(Suppl IV):IV56-IV62.
24. Ferrario CM, Schiavone MT. The renin angiotensin system: Importance in physiology and pathology. Cleve Clin J Med 1989;56:439-446.
25. Ferrario CM, Averill DB. The importance of angiotensin in the brain. In: Mornex R, Gaffial C, Leclere J, eds. Progress in Endocrinology. Lanes, England: Parthenon, 1993: 482-486.
26. Welches WR, Santos RAS, Chappell MC, Brosnihan KB, Greene LJ, Ferrario CM. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 1991;9:631-638.
27. Hanesworth JM, Sardinia MF, Krebs LT, Hall KL, Harding JW. Elucidation of a specific binding site for angiotensin II (3-8), angiotensin IV, in mammalian heart membranes. J Pharmacol Exp Ther 1993;266:1036-1042.
28. Sardinia MF, Hanesworth JM, Krebs LT, Harding JW. AT4 receptor binding characteristics: D-amino acid and glycine-substituted peptides. Peptides 1993;14:949-954.
29. Swanson GN, Hanesworth JM, Sardinia MF, et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992;40:409-419.
30. Griendling KK, Berk BC, Socorro L, Tsuda T, Delafontaine P, Alexander RW. Secondary signalling mechanisms in angiotensin II stimulated vascular smooth muscle cells. Clin Exp Pharmacol Physiol 1988;15:105-112.
31. Jaiswal N, Tallant EA, Diz DI, Khosla MC, Ferrario CM. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension 1991;17: 1115-1120.
32. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. Characterization of angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells. Am J Physiol 1991; 260:R1000-R1006.
33. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5:221S-235S.
34. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
35. Ichiki T, Inagami T. Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene. Circ Res 1995;76:693-700.
36. Ichiki T, Inagami T. Transcriptional regulation of the mouse angiotensin II type 2 receptor gene. Hypertension 1995;25:720-725.
37. Nakajima M, Horiuchi M, Morishita R, Yamada T, Pratt RE, Dzau VJ. Growth inhibitory function of type 2 angiotensin II receptor: Gain of function study by in vivo gene transfer (abstract). Hypertension 1994;24:379.
38. Tsutsumi K, Stromberg C, Viswanathan M, Saavedra JM. Angiotensin-II receptor subtypes in fetal tissues of the rat: Autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. Endocrinology 1993; 129:1075-1082.
39. Kaplan NM. Clinical Hypertension, 4th ed. Baltimore, MD: Williams & Wilkins, 1986.
40. Laragh JH, Brenner BM. Hypertension Pathophysiology, Diagnosis, and Management, 2nd ed. New York: Raven Press, 1995:1-1720.
41. Ferrario CM, Averill DB. Do primary dysfunctions in neural control of arterial pressure contribute to hypertension? Hypertension 1991;18(Suppl 1):138-151.
42. Von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. Circulation 1994;89:458-470.
43. Abboud FM. The sympathetic system in hypertension. Hypertension 1982;4(Suppl II):208-225.
44. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am Heart J 1994;127:1388-1401.
45. Moncada S. The L-arginine: Nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res 1993;28:97-99.
46. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-141.
47. Dusting GJ, Moncada S, Vane JR. Prostacyclin: Its biosynthesis, actions, and clinical potential. In: Oates JA, ed. Prostaglandins and the Cardiovascular System. New York: Raven Press, 1982:59-106.
48. Laragh JH. Conceptual diagnostic and therapeutic dimensions of renin-system profiling of hypertensive disorders and of congestive heart failure: Four new research frontiers. In: Doyle AE, Beam AG, eds. Hypertension and the Angiotensin System: Therapeutic Approaches. New York: Raven Press, 1984:47-72.
49. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-1104.
50. Cowley AW Jr, Roman RJ. The pressure-diuresis-natriuresis mechanism in normal and hypertensive states. In: Zanchetti A, Tarazi RC, eds. Handbook of Hypertension, Vol. 8: Pathophysiology of Hypertension - Regulatory Mechanisms. London: Elsevier Science, 1986: 295-314.
51. Brenner BM, Anderson S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol 1992;19:S1-S5.
52. Laragh JH. The renin system and four lines of hypertension research: Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. Hypertension 1992;20:267-279.
53. McCubbin JW, Page IH. Neurogenic component of chronic renal hypertension. Science 1963;139:210-215.
54. Ferrario CM, Barnes KL, Szilagyi JE, Brosnihan KB. Physiological and pharmacological characterization of the area postrema pressor pathways in the normal dog. Hypertension 1979;1:235-245.
55. Ferrario CM. Central nervous system mechanisms of blood pressure control in normotensive and hypertensive states. Chest 1983;83(Suppl):331-335.
56. Ferrario CM. Neurogenic actions of angiotensin II. Hypertension 1983;5(Suppl V):V73-V79.
57. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. Circulation 1994;89:493-498.
58. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 1993;88:1-14.
59. Skidgel RA, Jackman HL, Erdos EG. Metabolism of substance P and bradykinin by human neutrophils. Biochem Pharmacol 1991;41:1335-1344.
60. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-370.
61. Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens 1994;12(Suppl):S43-S47.
62. Lacourciere Y, Lefebvre J, Nakhle G, Faison EP, Snavely DB, Nelson EB. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: The design of a prospective, controlled study. J Hypertens 1994;12(Suppl 2):S49-S53.
63. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides 1993;14: 883-891.
64. Ferrario CM, Milsted A, Santos RAS. Renin, converting enzyme and angiotensin peptides: A review. In: Keane WF, ed. A Focus on the Clinical Effects of a Long-Acting ACE Inhibitor/Hypertension. New York: Raven Press, 1990:1-20.
65. Admiraal PJJ, Derkx, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990;15:44-55.
66. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-572.
67. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986;8: 476-482.
68. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
69. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
70. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
71. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem 1991;266:19192-19197.
72. Chappell MC, Welches WR, Brosnihan KB, Ferrario CM. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate. Peptides 1992;13: 943-946.
73. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-145.
74. Carretero OA, Orstavik TB, Rabito SF, Scicli AG. Interference of converting enzyme inhibitors with the kallikrein-kinin system. Clin Exp Hypertens 1983;A5:1277-1285.
75. Beierwaltes WH, Carretero OA. Kinin antagonist reverses converting enzyme inhibitor-stimulated vascular prostaglandin 12 synthesis. Hypertension 1989;13:754-758.
76. Bumpus FM. Angiotensin I and II; some early observations made at the Cleveland Clinic Foundation and recent discoveries relative to angiotensin II formation in human heart. Hypertension 1991;18:122-125.
77. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992;5:209S-220S.
78. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT receptor. Am J Hypertens 1992;5:276-280.
79. Dahlof B. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J Hypertens 1993;11(Suppl 3):S29-S35.
80. Stier CT Jr, Adler LA, Levine S, Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993;11(Suppl 3):S37-S42.
81. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl 2):S37-S42.
82. Averill DB, Tsuchihashi T, Khosla MC, Ferrario CM. Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory response evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla. Brain Res 1994;665: 245-252.
83. Kumagai H, Averill DB, Khosla MC, Ferrario CM. Role of nitric oxide and angiotensin II in the regulation of sympathetic nerve activity in spontaneously hypertensive rats. Hypertension 1993;21:476-484.
84. Brunner HR, Nussberger J, Waeber B. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens 1993; 11(Suppl 3):S53-S58.
85. Moriguchi A, Ferrario CM, Brosnihan KB, Ganten D, Morris M. Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene. Am J Physiol 1994;267:R786-R791.
86. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266: R1273-R1278.
87. Stoll M, Steckelings UM, Bottari SP, Metzger R, Unger TH. Role of angiotensin II receptor subtypes in endothelial growth regulation (abstract). J Hypertens 1994;12:S72.
88. Pratt RE, Wang D, Hein L, Dzau VJ. The AT2 isoform of the angiotensin receptor mediates myointimal hyperplasia following vascular injury (abstract). Hypertension 1992;20: 432.
89. Benter IF, Ferrario CM, Morris M, Diz D. Chronic intravenous angiotensin-(1-7) infusions activate antihypertensive mechanisms in spontaneously hypertensive rats (abstract). Am J Hypertens 1994;7:94A.
90. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Processing of angiotensin peptides by NG108-15 neuroblastoma X glioma hybrid cell line. Peptides 1990;11: 375-380.
91. Burnier M, Waeber B, Brunner HR. The advantages of angiotensin II antagonism. J Hypertens 1994;12:S7-S15.
92. Brunner HR, Christen Y, Munafo A, Lee RJ, Waeber B, Nussberger J. Clinical experience with angiotensin II receptor antagonists. Am J Hypertens 1992;5:243S-246S.
93. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C. Efficacy and safety of losartan in patients with essential hypertension (abstract). Am J Hypertens 1992;5:19A.
94. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers; inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-1342.
95. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-521.
96. Tsunoda K, Abe K, Hagino R, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6: 28-32.
97. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. Am J Hypertens 1992;5: 247S-251S.
98. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: Acute hemodynamic, hormonal, and renal effects. Am J Physiol 1992;263: H250-H256.
99. Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994; 12(Suppl 2):S31-S35.
100. Lacourciere Y, Lefebvre J, Nakhle G, Faison EP, Snavely DB, Nelson EB. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: The design of a prospective, controlled study. J Hypertens 1994;12(Suppl 2):S49-S53.